Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
Nuvectis axes ovarian cancer program after seeing phase 1b data
Nuvectis Pharma dropped plans to develop NXP800 in ovarian cancer after tallying two unconfirmed partial responses in a phase 1b study.
Nick Paul Taylor
Jul 31, 2025 9:15am
BerGenBio, following lead drug's failure, merges with Oncoinvent
Jul 1, 2025 7:00am
Ernexa's stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025 2:30pm
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Mar 31, 2025 10:25am
Acrivon stops testing Lilly castoff for ovarian, bladder cancer
Mar 26, 2025 7:05am
Sutro discards CEO, 50% of staff and lead ADC to save cash
Mar 14, 2025 7:05am
